Published October 5, 2013 | Version v1
Journal article

MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells

  • 1. Université Paris-Sud 11 CNRS UMR 8126 «Signalisation, noyaux et innovations en cancérologie», Institut de Cancérologie Gustave-Roussy, Université Paris-Sud 11, F-94805 Villejuif cedex, Paris (France)
  • 2. Departamento de Genética, Universidade do Estado do Rio de Janeiro, Instituto de Biologia Roberto Alcantara Gomes, 20550-013 Rio de Janeiro (Brazil)
  • 3. Departamento de Biofísica, Laboratório de Ciências Radiológicas, Universidade do Estado do Rio de Janeiro, Instituto de Biologia Roberto Alcantara Gomes, 20550-013 Rio de Janeiro (Brazil)
  • 4. Departamento de Genética/UERJ, Rua São Francisco Xavier, 524/sala 525-6, Maracanã, 20 550-013 Rio de Janeiro, RJ (Brazil)
  • 5. Departamento de Biologia Celular, Embriologia e Genética, Universidade Federal de Santa Catarina, 88040-900 Florianopolis, Santa Catarina (Brazil)
  • 6. Departamento de Biologia Geral, Universidade Federal Fluminense, Instituto de Biologia, 24020-141 Niterói, Rio de Janeiro (Brazil)

Description

MicroRNAs are non-coding RNAs involved in the regulation of gene expression including DNA damage responses. Low doses of low energy X-ray radiation, similar to those used in mammographic exams, has been described to be genotoxic. In the present work we investigated the expression of miR-34a; a well described p53-regulated miRNA implicated in cell responses to X-ray irradiation at low doses. Non-cancerous breast cell line MCF-10A and cancerous T-47D and MCF-7 cell lines were submitted to a low-energy X-ray irradiation (ranging from 28–30 Kv) using a dose of 5 Gy. The expression level of miR-34a, let-7a and miR-21 was assessed by qRT-PCR at 4 and 24 hours post-irradiation. DNA damage was then measured by comet assay and micronuclei estimation in MCF-10A and MCF-7 cell lines, where an increase of miR-34a levels could be observed after irradiation. The rate of apoptotic cells was estimated by nuclear staining and fluorescence microscopy. These experiments were also performed at low doses (3; 12 and 48 mGy) in MCF-10A and MCF-7 cell lines. We have observed an increase in miR-34a expression 4 hours post-irradiation at 5 Gy in MCF-10A and MCF-7 cell lines while its level did not change in T-47D, a breast cancer cell line bearing non-functional p53. At low doses, miR-34a was up-regulated in non-tumoral MCF-10A to a higher extent as compared to MCF-7. MiR-34a levels decreased 24 hours post-irradiation. We have also observed DNA damage and apoptosis at low-energy X-ray irradiation at low doses and the high dose in MCF-10A and MCF-7 4 and 24 hours post-irradiation relative to the mock control. Low energy X-ray is able to promote DNA strand breaks and miR-34a might be involved in cell responses to low energy X-ray DNA damage. MiR-34a expression correlates with X-ray dose, time after irradiation and cell type. The present study reinforces the need of investigating consequences of low dose X-ray irradiation of breast cells

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-231; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829672

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 231
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47065884
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
APOPTOSIS; DNA; GY RANGE 01-10; IRRADIATION; MAMMARY GLANDS; NEOPLASMS; RADIATION DOSES; STRAND BREAKS; X RADIATION
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DISEASES; DNA DAMAGES; DOSES; ELECTROMAGNETIC RADIATION; GLANDS; GY RANGE; IONIZING RADIATIONS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; RADIATION DOSE RANGES; RADIATIONS

Optional Information

Copyright
Copyright (c) 2013 Stankevicins et al.
Notes
PMCID: PMC3829672; PUBLISHER-ID: 1748-717X-8-231; PMID: 24094113; OAI: oai:pubmedcentral.nih.gov:3829672; licensee BioMed Central Ltd.